PubMed ID: 19404046Statins are one of the most widely used drugs in medical treatment and have been shown to prevent cardiovascular disease or reduce risk in a large number of studies. Although there is a general class effect, there are differences with regard to structure and efficacy between these agents. Among these agents, atorvastatin is a potent statin whose efficacy has been demonstrated in many clinical trials. Despite the presence of numerous clinical studies, data on atorvastatin related to primary prevention are limited compared to secondary prevention. In this article, clinical results of primary prevention trials with atorvastatin and data on its cost-effectiveness are reviewed. It is concluded that atorvastatin has a role in p...
The review summarises data on statins efficacy in primary prophylaxis of cardiovascular complication...
Summary. The article examined the relationship between the risk of stroke and various profiles of li...
1-10OBJECTIVES: 8% of total drug spending by the Belgian government goes to statins. The aim of this...
Atorvastatin has been extensively studied in the primary and secondary prevention of cardiovascular ...
We estimated the cost-effectiveness of atorvastatin treatment in the primary prevention of cardiovas...
AIMS/HYPOTHESIS: We estimated the cost-effectiveness of atorvastatin treatment in the primary preven...
AbstractBackgroundThe literature on the cost-effectiveness of statin drugs in primary prevention of ...
Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and se...
Introduction: Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the enzyme re...
Cardiovascular disease (CVD) is the leading cause of death worldwide. Dyslipidemia is one of the cau...
Aims: The results of the West of Scotland Coronary Prevention Study (WOSCOPS) demonstrated the clini...
The article reviews current approaches to primary prevention of cardiovascular events and risk-benef...
Objectives - 8% of total drug spending by the Belgian government goes to statins. The aim of this st...
Several studies have shown that treatment with HMG-CoA reductase inhibitors (statins) can reduce cor...
<p>The definition of primary prevention of cardiovascular diseases is presented. Statins preventive ...
The review summarises data on statins efficacy in primary prophylaxis of cardiovascular complication...
Summary. The article examined the relationship between the risk of stroke and various profiles of li...
1-10OBJECTIVES: 8% of total drug spending by the Belgian government goes to statins. The aim of this...
Atorvastatin has been extensively studied in the primary and secondary prevention of cardiovascular ...
We estimated the cost-effectiveness of atorvastatin treatment in the primary prevention of cardiovas...
AIMS/HYPOTHESIS: We estimated the cost-effectiveness of atorvastatin treatment in the primary preven...
AbstractBackgroundThe literature on the cost-effectiveness of statin drugs in primary prevention of ...
Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and se...
Introduction: Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the enzyme re...
Cardiovascular disease (CVD) is the leading cause of death worldwide. Dyslipidemia is one of the cau...
Aims: The results of the West of Scotland Coronary Prevention Study (WOSCOPS) demonstrated the clini...
The article reviews current approaches to primary prevention of cardiovascular events and risk-benef...
Objectives - 8% of total drug spending by the Belgian government goes to statins. The aim of this st...
Several studies have shown that treatment with HMG-CoA reductase inhibitors (statins) can reduce cor...
<p>The definition of primary prevention of cardiovascular diseases is presented. Statins preventive ...
The review summarises data on statins efficacy in primary prophylaxis of cardiovascular complication...
Summary. The article examined the relationship between the risk of stroke and various profiles of li...
1-10OBJECTIVES: 8% of total drug spending by the Belgian government goes to statins. The aim of this...